FOLH1 and posterior cortical atrophy: Diverse PSMA-directed antibodies, antibody-derivatives, peptides, peptidomimetics, small molecules, and nanoparticles have been designed as capable diagnostic, therapeutic, and/or theranostic constructs for the management of PCa (110–113).